Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients

Clinical Microbiology and Infection

Volumn 9, Issue 11, 2003, Pages 1128-1132

  Frank, U ^a   Mutter, J ^a   Schmidt Eisenlohr, E ^a   Daschner, F D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Nosocomial pathogens; Susceptibility testing; lactamase inihibitor

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE INHIBITOR; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MECHANISM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE; NONHUMAN; PRIORITY JOURNAL; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; PROTEUS VULGARIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0242539744     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00786.x     Document Type: Article

References (20)

1. Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989; 12: 482-8.
2. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; eighth informational supplement. M100-S8. Wayne, Pa: NCCLS, 1998: 46-78.
3. Brismar B, Malmborg AS, Tunevall G et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36: 2766-73.
4. Vestweber KH, Grundel E. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections. Eur J Surg Suppl 1994; 573: 57-60.
5. Jaccard C, Troillet N, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72.
6. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R et al. Spanish Collaborative Group for the Study of Severe Infections. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27: 493-502.
7. Speich R, Imhof E, Vogt M, Grossenbacher M, Zimmerli W. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 313-17.
8. Tassler H, Cullmann W, Elhardt D. Therapy of soft tissue infections with piperacillin/tazobactam. J Antimicrob Chemother 1993; 31: 105-12.
9. Nowe P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994; 20(suppl 3): S39-42.
10. Hess U, Bohme C, Rey K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6: 402-9.
11. Cometta A, Zinner S, de Bock R et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445-52.
12. Payne DJ, Cramp R, Winstanley DJ, Knowles DJC. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother 1994; 38: 767-72.
13. Fleischhack G, Schmidt-Niemann M, Wulff B et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001; 9: 372-9.
14. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 1989; 33: 1964-9.
15. Seewald M. In-vitro activity of piperacillin alone and combined with sulbactam or tazobactam against hospital-derived pathogens [abstract WeP60]. Clin Microbiol Infect 2000; 6(suppl 1): 77.
16. Lister PD, Prevan AM, Sanders CC. Importance of β-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother 1997; 41: 721-7.
17. Schubert S, Ullmann U. Comparative bactericidal activity of piperacillin-tazobactam and piperacillin-sulbactam against piperacillin-resistant E. coli strains [abstract WeP85]. Clin Microbiol Infect 2000; 6(suppl 1): 84.
18. Finegold SM. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999; 12(suppl 1): S9-14.
19. Frank U, Daschner FD. In vitro activity of sulbactam plus ampicillin against hospital isolates of coagulase-negative staphylococci and Acinetobacter species. Infection 1989; 17: 272-4.
20. De la Pena A, Derendorf H. Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 1999; 37: 63-75.